Semaglutide vs Tirzepatide

The cleanest way to think about this matchup is receptor coverage. Semaglutide is a single-target GLP-1 agonist; tirzepatide is dual, hitting GLP-1 and GIP at the same time. The dual hit is the entire reason the published weight-loss numbers for tirzepatide land higher in head-to-head trials — SURMOUNT-1 reported about 22.5 percent average loss at 72 weeks against the roughly 15 percent semaglutide showed in STEP-1. The cadence in a tracker is identical (one shot a week), but the titration ladders are not interchangeable, and dose strings on the syringe are not the same numbers.

Tirzepatide's titration ladder climbs through 2.5, 5, 7.5, 10, 12.5, and 15 mg, with the early steps spent largely getting the gut tolerant rather than chasing weight loss. Semaglutide's path runs 0.25, 0.5, 1.0, 1.7, 2.4 mg with the same logic. A reader logging both in the same calendar will notice that tirzepatide's middle steps are where most of the loss shows up, while semaglutide tends to feel more linear week to week. Neither curve is a guarantee for any individual person, which is why a well-kept log matters more than the trial average.

Side-effect profile reads similarly in the two molecules — nausea, transient constipation, and the appetite-suppression that drives most of the weight loss — but tirzepatide's GIP component changes the texture of the early weeks for some people, and the gut-tolerance window is the place a careful log earns its keep. Both molecules carry the same boxed warning around C-cell tumors in rodents, both are administered with the same kind of insulin syringe or pre-filled pen, and both reconstitute identically when sourced as lyophilized powder from a research supplier.

Practically, the question that brings most people to this page is which one to plan around for a six-month log. The answer is structural rather than chemical: tirzepatide tends to require fewer dose-tolerance retreats but a longer total ramp, while semaglutide's lower-dose plateau is shorter and easier to sit on if the goal is steady-state rather than maximum loss. The calculator pages linked below let you plug your own vial size and dose into the math; the table at the top of this page does the comparison at the example vials only.

For the Semaglutide vs Tirzepatide decision specifically, the calendar shape is what most readers underweight. Semaglutide's example vial is 5 mg drawn against 0.25 mg per dose at 1 dose per week. Tirzepatide's example vial is 10 mg drawn against 2.5 mg per dose at 1 dose per week. Those four numbers feed every column in the table above; change any one and the semaglutide vs tirzepatide comparison shifts with it.

Concentration in this pair: Semaglutide sits at 2.50 mg/mL on the example reconstitution; Tirzepatide sits at 5.00 mg/mL on its example. That single ratio is what determines how many U-100 syringe units a given dose of either molecule actually draws, so it is the first thing to confirm before treating any "Semaglutide vs Tirzepatide" unit number on the internet as authoritative.

Doses per vial in this matchup work out to roughly 20 for Semaglutide and 4 for Tirzepatide at the example dose sizes, with vial-duration windows near 20.0 weeks and 4.0 weeks respectively. Refill cadence follows directly from those windows, which is why the semaglutide vs tirzepatide pair shows up in planning conversations more than in pure mechanism conversations.

When readers compare Semaglutide against Tirzepatide, the Semaglutide-side mistakes that show up most in logs are: Switching to a new vial of the same peptide and reusing the old unit count without re-running the calculation against the new vial's diluent volume. Storing reconstituted semaglutide at room temperature for hours before refrigerating, especially after a travel day. Dosing twice in the same week after forgetting whether the previous injection was Sunday or Monday — almost always a logging-gap problem, not a math problem. Reading 0.25 mg as 25 units on the syringe regardless of vial concentration. The unit count is not fixed — it depends on the diluent volume. Each of these gets amplified when a reader is also actively comparing against Tirzepatide, because muscle memory from one molecule's unit math leaks into the other.

Semaglutide question worth answering up front — How is semaglutide reconstituted? By adding a measured volume of bacteriostatic water to the lyophilized vial through the rubber stopper, then swirling — not shaking — until the powder fully dissolves into a clear solution. The exact diluent volume is up to the user; common choices for a 5 mg vial are 1, 2, or 3 mL.

Semaglutide question worth answering up front — How many units of semaglutide are in 0.25 mg? It depends on the concentration of your vial. On a 5 mg vial reconstituted with 2 mL of bacteriostatic water, 0.25 mg is exactly 10 units on a U-100 insulin syringe. On a 5 mg vial reconstituted with 1 mL, the same dose is 5 units.

On the Tirzepatide side of the Semaglutide vs Tirzepatide decision, the recurring mistakes are: Reusing the unit count from a previous vial after switching to a new vial that was reconstituted with a different diluent volume. Skipping the escalation date in the log, then being unable to answer when a dose change actually happened. Mixing up tirzepatide milligrams with semaglutide milligrams — the doses are typically much larger for tirzepatide and the math is not interchangeable. Underestimating doses-per-vial on a high-strength vial because the vial looks small even though it contains many weeks of supply. These are not generic dosing slips — they are the ones that compound when Tirzepatide is being logged in parallel with Semaglutide.

Tirzepatide question worth answering up front — How is tirzepatide reconstituted? By drawing a measured volume of bacteriostatic water and injecting it slowly into the lyophilized vial through the rubber stopper, then swirling — not shaking — until the powder fully dissolves. Diluent volume choices typically range from 2 to 5 mL depending on vial strength and preferred per-dose unit count.

Tirzepatide question worth answering up front — How many units of tirzepatide are in 2.5 mg? It depends on the concentration. On a 10 mg vial reconstituted with 2 mL of bacteriostatic water (5 mg per mL), 2.5 mg is exactly 50 units on a U-100 syringe. With 4 mL of diluent (2.5 mg per mL), the same dose is 100 units.